Navigation Links
One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
Date:5/8/2009

ed."

Therapeutic opportunity

In September 2006, Rensselaer signed a licensing agreement granting Massachusetts-based biotechnology company Alkermes exclusive rights to a library of compounds discovered by Wentland and his team.

According to Alkermes, the library represents an opportunity for the company to develop numerous products as important therapeutics for the treatment of a broad range of diseases and medical conditions, including addiction, pain, and other nervous system disorders. Alkermes screened the library of compounds from Rensselaer and is responsible for the continued research and development of any resulting product candidates.

This year, Alkermes held its Research and Development Day meeting for analysts and investors in Cambridge, Mass., on April 7 and provided an overview of its product candidates, including ALKS 33. Preclinical studies of ALKS 33 suggested that it was not readily metabolized by the liver, a unique advantage over existing oral therapies for addiction. According to the company, initiation of the phase 1 trial of ALKS 33 was based on the compound's potential for a superior pharmacokinetic profile and the compound's pharmacological properties relative to other commercial opioid antagonists.

According to Alkermes, data from the phase 1 study of ALKS 33 showed that the compound is absorbed rapidly into the bloodstream, and has a pharmacokinetic profile that could support once-daily dosing.

"This latest discovery is the result of an interdisciplinary collaboration between chemists and biologists," Wentland said. "In the process, we are working together to identify novel therapies to treat human diseases and find possible solutions that work. Most importantly, this discovery allows us to see the significant role that biotechnology plays in improving health, creating new materials for myriads of applications, and addressing some of the w
'/>"/>

SOURCE Rensselaer Polytechnic Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July ... ), a leading global pharmaceutical company, and Oculeve, a ... for dry eye disease, today announced that they have ... Oculeve in an all-cash transaction.  Under the terms of ... million upfront payment and commercialization milestone payments related to ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... ... Anticancer Drug, HOUSTON, ... to families, workplaces and communities, and many,Houstonians are aware of ... the CHRISTUS Stehlin Foundation for,Cancer Research, a nationally recognized leader ...
Journalists and other readers should disregard the news release "Oramed,Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository",OTC:ORMP, issued earlier today. The release was transmitted...
Cached Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
(Date:7/7/2015)... New York (PRWEB) , ... July 07, 2015 , ... ... a wide array of charitable organizations on a local, national and international level; however, ... an organization they believe will have a high impact on the beneficiaries. In September ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... Revival System that eliminates 100% of all acids, chemicals and impurities; it also ... for drinking water because it contains harmful contaminants.  These harmful contaminants are a ...
(Date:7/6/2015)... ... ... Shortly after opening her second practice in Signal Hill, Dr. Sue Lim ... lien basis. Dr. Lim had previously worked with Dr. Kevin Kelly, DC a ... Lim suffered with back pain herself throughout high school. Unaware of the benefits ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce ... Teaching Award on behalf of the department of Family Practice. , “This award is ... be practicing in. The technology is changing so rapidly and we are also developing ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Seedstock today ... the keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and ... conference , held at the University of California-San Diego, will explore solutions and ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4
... value in health care: What should we pay for and ... health care should be balanced against various realities--including the effectiveness ... Especially in a depressed economy, questions about value in health ... reform debates. , In a commentary published in Health ...
... 26 Krause, Kalfayan, Benink & Slavens, LLP filed ... Court on behalf of a putative class of California ... years, Scripps Health billed for medical services after their ... emergency medical bills. The lawsuit alleges that ...
... COLUMBUS, Ga., Jan. 26 Aflac Incorporated,announced today that ... will webcast a conference call scheduled for 9:00 a.m. ... in addition to the previously,announced fourth quarter webcast meeting ... During the morning teleconference on February 3, ...
... For Needed Enforcement of Canon 915; Withholding Eucharist From ... American Life League executive director Shaun Kenney issued the ... Pelosi,s interview with ABC News on Sunday. Rep. Pelosi ... in the economic stimulus package would "reduce costs to ...
... on interoperability specifications from the Healthcare Information Technology Standards Panel ... ... Chicago (Vocus) January 26, 2009 -- With the economic ... domestic priorities identified in Tuesday,s inaugural address, with President Obama ...
... United American Healthcare,Corporation (Nasdaq: UAHC ), a ... financial results for the second fiscal,quarter ended December 31, ... The Company will host a conference call at 4:30 ... , Participation in the call,s ...
Cached Medicine News:Health News:Can payment and other innovations improve the quality and value of health care? 2Health News:KRAUSE, KALFAYAN, BENINK & SLAVENS, LLP, Announces Filing a Class Action Lawsuit Against Scripps Health, et al. 2Health News:Aflac Announces Additional Teleconference Webcast 2Health News:American Life League Statement on Pelosi's State-Enforced War on Preborn Babies 2Health News:Achieving Interconnected Healthcare through HITSP Real-Life Scenarios 2Health News:Achieving Interconnected Healthcare through HITSP Real-Life Scenarios 3Health News:Achieving Interconnected Healthcare through HITSP Real-Life Scenarios 4Health News:Achieving Interconnected Healthcare through HITSP Real-Life Scenarios 5Health News:Achieving Interconnected Healthcare through HITSP Real-Life Scenarios 6Health News:United American Healthcare Corporation to Host Fiscal 2009 Second Quarter Results Conference Call February 5th 2
... Split Splint reduces PIP joint or DIP joint ... to put on. Soft gel-lining cushions injured fingers ... begin earlier for faster, more successful therapy results. ... and at night to maintain gains in motion. ...
... FoamWrap Final Flexion Wraps restore full PIP ... or when lost due to arthritic changes. ... foam-lined material hugs the finger to prevent ... restore motion. One size. Sold in packages ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
Medicine Products: